The Potential Role of

Area of Science:

• Pharmacogenomics
• Clinical Chemistry
• Psychiatry

Background:

• Clozapine (CLZ) is a vital antipsychotic for treatment-resistant schizophrenia.
• Its clinical use is limited by a narrow therapeutic index and serious adverse effects.
• Understanding CLZ metabolism is crucial for safe and effective treatment.

Purpose of the Study:

• To investigate the impact of genetic variations in CYP1A2 and Cytochrome P450 oxidoreductase (POR) on clozapine (CLZ) and N-desmethylclozapine (DCLZ) plasma levels.
• To explore the influence of these genetic factors in conjunction with non-genetic factors like smoking and caffeine consumption.

Main Methods:

• Analyzed plasma CLZ and DCLZ levels in 112 schizophrenia patients using High-Performance Liquid Chromatography (HPLC).
• Identified genetic variations in CYP1A2 and POR using the Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) method.
• Conducted subgroup analyses to assess the influence of genotypes and environmental factors.

Main Results:

• No significant effect of CYP1A2 or POR genotypes on overall plasma CLZ and DCLZ levels was observed.
• In subgroup analysis, the POR*28 genotype significantly affected CLZ and DCLZ levels, particularly when considering smoking habits and caffeine consumption.
• This suggests a complex interplay between genetic and environmental factors in CLZ pharmacokinetics.

Conclusions:

• Individualizing clozapine (CLZ) treatment requires consideration of both genetic factors and non-genetic influences such as smoking and caffeine intake.
• Cytochrome P450 oxidoreductase (POR), essential for CYP enzyme activity, may be a valuable target alongside metabolizing enzymes for guiding CLZ dosing.
• These findings support a more personalized approach to clozapine therapy for improved clinical decision-making.